How do I find out if I qualify for a refractory non-hodgkin lymphoma study in District of Columbia?

Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.

Do I have to live in District of Columbia to take part?

Not necessarily. These studies have a site in District of Columbia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.

Does it cost anything to join a refractory non-hodgkin lymphoma trial?

Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.

Clinical trials · District of Columbia

Refractory Non-Hodgkin Lymphoma clinical trials in District of Columbia

We’re tracking 4 recruiting refractory non-hodgkin lymphoma studies with a site in District of Columbia — including Phase 1, Phase 1/Phase 2 and Phase 3 studies, each written for real people, not researchers.

Recruiting studies in District of Columbia

NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Washington D.C., District of ColumbiaAges 18 years+
NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Washington D.C., District of ColumbiaAges 1–30
NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Washington D.C., District of ColumbiaAges 18 years+
NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Washington D.C., District of ColumbiaAges 1–21

Refractory Non-Hodgkin Lymphoma trials by city in District of Columbia

Washington, D.C.

Where these studies are running in District of Columbia

Institutions with a site for the recruiting refractory non-hodgkin lymphoma studies listed above.

Children's National Medical Center · 2 studies
MedStar Georgetown University Hospital · 2 studies

What taking part in a refractory non-hodgkin lymphoma study involves

A screening visit first

Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.

Care at a nearby site

Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.

You stay in control

Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.

The team decides eligibility

Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.

Refractory Non-Hodgkin Lymphoma trials in other states

Common questions

Are there refractory non-hodgkin lymphoma clinical trials in District of Columbia?: Yes. We're currently tracking 4 recruiting refractory non-hodgkin lymphoma studies with a site in District of Columbia, each rewritten in plain language so you can see what it's testing and who it's for.
How do I find out if I qualify for a refractory non-hodgkin lymphoma study in District of Columbia?: Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
Do I have to live in District of Columbia to take part?: Not necessarily. These studies have a site in District of Columbia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
Does it cost anything to join a refractory non-hodgkin lymphoma trial?: Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.

Not the right time?

New refractory non-hodgkin lymphoma studies open in District of Columbia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.

Get told when a study that fits you opens

Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.